SCHEMBL14733506

SCHEMBL14733506

C#Cc1cccc(Nc2ncnc3ccc4nc(C#N)sc4c23)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.67
DYRK1B Q9Y463 4/20 0.67
EGFR P00533 11/20 0.50
GAK O14976 3/20 0.48
FBP1 P09467 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
ABCG2 Q9UNQ0 2/20 0.48
RIPK2 O43353 2/20 0.45
BUB1 O43683 2/20 0.45
STK10 O94804 2/20 0.45
MAP3K1 Q13233 2/20 0.45
PIP4K2C Q8TBX8 2/20 0.45
SLK Q9H2G2 2/20 0.45
CARS1 P49589 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ERBB2 P04626 2/20 0.45
ERBB4 Q15303 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14733418 0.92 DYRK1A (0.70) DYRK1ADYRK1BEGFRABCG2HDAC3
SCHEMBL14733462 0.85 DYRK1A (0.64) DYRK1ADYRK1BEGFRMAPTERBB2
SCHEMBL16038266 0.84 DYRK1A (0.60) DYRK1ADYRK1BEGFRMAPTABCG2
SCHEMBL17060623 0.82 DYRK1A (0.73) DYRK1ADYRK1BEGFRHDAC3HDAC1
SCHEMBL14733542 0.81 DYRK1A (0.68) DYRK1ADYRK1BABCG2
SCHEMBL14733471 0.80 DYRK1A (1.00) DYRK1ADYRK1B
SCHEMBL14733493 0.79 DYRK1A (0.63) DYRK1ADYRK1BCDK2DYRK2
SCHEMBL17060597 0.78 DYRK1A (0.73) DYRK1ADYRK1BEGFRABCG2HDAC3
SCHEMBL14733529 0.78 DYRK1A (0.62) DYRK1ADYRK1BMAPTRAF1
SCHEMBL14733587 0.78 DYRK1A (0.62) DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446044-B2 DYRK1 inhibitors and uses thereof DIAXONHIT (FR) 2016-09-20 US disclosed
US-9446044-B2 DYRK1 inhibitors and uses thereof DIAXONHIT (FR) 2016-09-20 US disclosed
EP-2744797-B1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2015-09-09 EP disclosed
EP-2744797-B1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2015-09-09 EP disclosed
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2014-09-18 US disclosed
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2014-09-18 US disclosed
WO-2013026806-A1 DYRK1 INHIBITORS AND USES THEREOF EXONHIT SA (FR) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885DYRK1B 2/4885EGFR 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.